Phathom Pharmaceuticals Announces The Appointment Of Anne Marie Cook As Chief Legal Officer And Corporate Secretary To Lead Legal And Governance Strategy
Phathom appoints Anne Marie Cook as Chief Legal Officer to support its growth in GI therapeutics.
Breaking News
Jun 25, 2025
Simantini Singh Deo

Phathom Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapies for gastrointestinal (GI) diseases, has announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook brings extensive legal and leadership experience within the pharmaceutical industry. She has a strong background in corporate governance, regulatory compliance, commercial law, strategic transactions, and legal risk management.
Steven Basta, President and Chief Executive Officer of Phathom Pharmaceuticals, said in a statement, “I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years. Anne Marie will play a key role in shaping our corporate strategy.”
Anne Marie Cook, stated, “I’m honored to join Phathom at such an exciting stage in its commercial evolution. Phathom has the potential to redefine the standard of care in acid-related GI diseases, and I’m energized by the opportunity to contribute to the company’s next chapter and to help create value for patients, physicians, and shareholders.”
Before joining Phathom, she served as Senior Vice President and General Counsel at Sage Therapeutics, Inc., where she oversaw legal strategy and supported the company’s commercial and regulatory activities. Earlier in her career, Ms. Cook held senior legal roles at Aegerion Pharmaceuticals, ViaCell, and Biogen, contributing to a range of initiatives across corporate law, product development, and compliance in both public and private life sciences companies. With her appointment, Phathom aims to strengthen its legal and corporate governance capabilities as it continues to advance its pipeline of GI-focused therapies and navigate the evolving regulatory and commercial landscape.”